Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Exploring the Interplay Between Maternal Stress, Human Milk, and Epigenetic Changes in Preterm Infant's Neurodevelopment (EMBRACE)

11 de novembro de 2026 atualizado por: Camilla Fontana, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Preterm birth represents a major challenge in pediatric healthcare, as preterm infants are at increased risk of neonatal complications and long-term neurodevelopmental impairments. Several factors may contribute to these outcomes, including gestational age at birth, postnatal comorbidities, and the neonatal intensive care unit (NICU) environment. Furthermore, preterm birth and prolonged hospitalization may negatively affect maternal psychological well-being, increasing the risk of stress, anxiety, and depression. These conditions may influence maternal sensitivity and responsiveness, mother-infant interactions, and infant neurodevelopment.

Emerging evidence suggests that maternal mental health may affect infant neurodevelopment through both direct biological mechanisms, such as epigenetic regulation, and indirect pathways, including changes in breast milk composition. Cortisol, a stress-related hormone present in breast milk and saliva, may play a role in stress regulation and neurobehavioral development. In particular, the methylation of Long Interspersed Nuclear Element-1 (LINE-1 or L1), a mobile genetic element involved in genomic regulation, may be influenced by environmental factors and early maternal care. Preliminary findings indicate that preterm infants exhibit lower L1 promoter methylation levels at birth than term infants, while early maternal care may modulate these levels and support neurobehavioral development.

The EMBRACE study aims primarily to investigate the relationship between biological maternal stress, measured through salivary cortisol levels, and L1 promoter methylation in blood samples collected from preterm infants from birth to 12 months of corrected age. Secondary objectives include examining this relationship in buccal swab samples, assessing associations between maternal perceived stress, anxiety, and depression and infant L1 methylation, and investigating the relationship between maternal psychological and biological stress indicators and infant neurodevelopmental outcomes. The study will also explore associations between perceived maternal stress and cortisol concentrations in breast milk and saliva, as well as longitudinal changes in L1 methylation.

This is a non-pharmacological, observational cohort study conducted at the Neonatology and Neonatal Intensive Care Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy. Participants will include preterm infants born between 24+0 and 30+6 weeks of gestational age and their mothers. Assessments will be conducted at five time points: birth, transition to intermediate care or 34 weeks of postmenstrual age, hospital discharge, 6 months, and 12 months of corrected age. Maternal assessments will include standardized questionnaires evaluating stress, anxiety, and depression, as well as cortisol measurements in saliva and breast milk. Infant assessments will include L1 methylation analyses in blood and buccal samples and standardized neurodevelopmental evaluations as part of routine clinical follow-up. No additional invasive procedures will be performed, as blood samples will be collected during routine clinical care.

The study is expected to improve understanding of the relationships between maternal stress, anxiety, depression, epigenetic regulation, and neurodevelopment in preterm infants. It will also investigate the potential role of breast milk cortisol in these associations. Ultimately, the findings may contribute to the development of early interventions aimed at improving neurodevelopmental outcomes in preterm infants and supporting maternal psychological well-being.

Visão geral do estudo

Tipo de estudo

Observacional

Inscrição (Estimado)

96

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Lombardy
      • Milan, Lombardy, Itália, 20122
        • Recrutamento
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • Contato:
        • Subinvestigador:
          • Chiara Bonfanti
        • Subinvestigador:
          • Agnese De Carli
        • Subinvestigador:
          • Monica Fumagalli
        • Subinvestigador:
          • Mary Giorgia Gaccione

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

5 meses a 6 meses (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

All preterm infants born at the SC Neonatologia e Terapia Intensiva Neonatale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano and their mothers.

Descrição

Inclusion Criteria:

  • Preterm infants born between 24+0 and 30+6 weeks of gestational age (GA);
  • Mothers aged ≥ 18 years with adequate understanding of the Italian language;
  • Signed informed consent from parents.

Exclusion Criteria:

  • Parents decline participation;
  • Infants with major congenital anomalies, malformations, or genetic syndromes;
  • Mothers with obvious psychiatric conditions, cognitive deficits, or active substance abuse at the time of delivery.
  • Infants birth samples not available (both buccal swab and blood)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Epigenetic changes on LINE1 (blood samples)
Prazo: up to 48 weeks post menstrual age

epigenetic analysis is performed on cord blood samples collected at birth, at transition to intermediate care and at hospital discharge on peripheral blood samples

up to 48 weeks post menstrual age
Maternal salivary cortisol
Prazo: up to 12 months corrected age of the infant

Collected at birth, transition to intermediate care, discharge

up to 12 months corrected age of the infant

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Human milk cortisol concentrations
Prazo: up to 6 months corrected age of the infant

Collected at birth, transition to intermediate care, discharge

up to 6 months corrected age of the infant
Buccal swab
Prazo: up to 12 months corrected age

Collected at birth, 34 weeks GA, discharge, 6 and 12 months corrected age

up to 12 months corrected age
Neurological outcome
Prazo: up to 44 weeks post menstrual age

Hammersmith neonatal neurological examination performed at NICU discharge

up to 44 weeks post menstrual age
Neonatal Visual Assessment
Prazo: up to 44 weeks post menstrual age

Neonatal visual function in assessed at discharge using the Visual Assessment battery developed by Ricci et al. The assessment has 9 items and each one is scored as normal or abnormal according to the description given by the authors.

up to 44 weeks post menstrual age
Neonatal behavior
Prazo: up to 44 weeks post menstrual age

Neonatal behavior is assessed using the Neonatal Behavior Assessment Scale, and in particular the areas of state organization, state regulation, and the autonomic system. Each item will be scored according to the description given by the author of the assessment

up to 44 weeks post menstrual age
Neurodevelopmental outcome
Prazo: from 6 to 12 months corrected age

Bayley scales to assess neurodevelopment at 6 and 12 months corrected age. The normal range for the composite score is 100 +/- 15 points. Higher scores mean better outcomes.

from 6 to 12 months corrected age
Maternal depression
Prazo: up to 12 months corrected age of the infant

Assessed with the Edinburgh Postnatal depression scale. Responses are scored 0 to 3. A score above 8 is considered pathological in the post partum period. It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age.

up to 12 months corrected age of the infant
Maternal stress in the NICU
Prazo: up to 12 months corrected age of the infant

Assessed with the Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU). It is composed of 35 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressfull). It will be administered at birth, at transition to intermediate care and at NICu discharge.

up to 12 months corrected age of the infant
Maternal bonding
Prazo: up to 12 months corrected age of the infant

Assessed with the Postpartum Bonding Questionnaire (PBQ) administered at NICU discharge, 6 and 12 months corrected age. A score above 26 is considered pathological.

up to 12 months corrected age of the infant
Maternal anxiety and depression
Prazo: up to 12 months corrected age of the infant

Assessed with the hospital anxiety and depression scale (HAD-S). It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age. A score from 0 to 7 is normal, 8-10 borderline and 11-21 score in the clinical range.

up to 12 months corrected age of the infant
Parenting stress
Prazo: up to 12 months corrected age of the infant

Assessed with the Parenting Stress Index Scale. Administered at 6 and 12 months corrected age. It is composed of 36 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressful)

up to 12 months corrected age of the infant

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

25 de agosto de 2026

Conclusão Primária (Estimado)

1 de junho de 2027

Conclusão do estudo (Estimado)

1 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

5 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • EMBRACE

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever